Message #7 From:
NewsBot Date: August 24, 2006 08:34:00 AM
HBSC News Human BioSystems Invites Interested Parties, Shareholders and Listeners to Hear HBSC's CEO Speak on Ethanol
PALO ALTO, Calif.--(BUSINESS WIRE)--Aug. 24, 2006--Human BioSystems (OTCBB:HBSC), announced today that Harry Masuda, CEO, will be discussing the topic of ethanol production on a variety of radio stations and invites listeners, interested parties, and shareholders in those areas to tune in to receive important information on the company's planned expansion into the production of biofuels, specifically ethanol.
His scheduled appearances are detailed as follows:
Thursday, August 24, 2006
KFYR AM 550 Radio - North Dakota
3:10 CST
Friday, August 25, 2006
KZIM News Radio 960 AM, Missouri
12:30 am CST
Monday, August 28, 2006
WKEB 99.3 FM Radio & WIGM 1490 AM Radio - Medford, Wisconsin,
10:15 am CST
Wednesday, August 30, 2006
KFOR 1240 AM Radio - Lincoln, Nebraska
10:00 am CST
Thursday, August 31, 2006
KXYL FM 96.9
5:15 pm CST
Tuesday, September 5, 2006
KFWB News 980 AM Radio, Los Angeles, CA
Online: http://www.kfwb.com
9:00 am PST
Wednesday, September 6, 2006
Market News First Radio, Texas
Online: http://www.mn1.com
2:00 pm CST
Human BioSystems, the developer of preservation platforms for organs and platelets, recently signed a letter of intent to enter into the BioFuels business through the acquisition of two ethanol production facility projects. The Palo Alto based Company, has made significant progress in its nine-year history to maximize its zone of responsibility for the health and welfare of the people and their environments.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
